Please login to the form below

Not currently logged in
Email:
Password:

VC firm expands team, appoints Genzyme and Lilly veterans

New roles for James Geraghty, Steven Paul, Daniel Lynch and John Maraganore

Third Rock Steven PaulUS venture capital company Third Rock Ventures has expanded its team by appointing a number of industry heavyweights.

The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies.

James Geraghty, who has spent 20-years at Genzyme, becomes entrepreneur-in-residence, while the former president of Lilly Research Laboratories, Steven Paul (pictured right), takes on an increased role at Third Rock with a position as a venture partner.

Third Rock Daniel LynchAlso joining Third Rock as venture partners are Daniel Lynch (pictured right), a former CEO of ImClone Systems, and Alnylam's CEO John Maraganore. 

Robert Tepper, partner at Third Rock Ventures, said: “These leaders have demonstrated - through decades of experience - their ability to integrate science and business.

“The depth of their expertise across commercial, business development, R&D, drug discovery and product development will be invaluable to Third Rock as we focus on translating scientific innovation into exceptional companies that make a difference for patients.”

15th May 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....